Chloroquine Population Pharmacokinetics in Pre and Post-partum Women

Vivax Malaria Clinical Trial

— KCP  

Official title:

The Population Pharmacokinetics of Chloroquine for the Treatment of Uncomplicated P.Vivax Malaria in Pre- and Post-partum Women.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01546961
• Other study ID #: SMRU1003
• Status: Completed
• Phase: N/A
• Start date: June 2011
• Est. completion date: May 2017

Study information

• Verified date: January 2019
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

For the treatment of P.vivax the standard treatment is chloroquine. There is a growing body of evidence suggesting that pregnant women may require different doses of drugs, including antimalarials due to the physiological changes of pregnancy. It is important that any drug used in pregnant women it is given at the correct dose. The only way to evaluate this is by pharmacokinetic studies. The investigators propose to evaluate the pharmacokinetics of chloroquine when use to treat P.vivax in the 2nd or 3rd trimester of pregnancy. The same evaluation in the same woman post-partum is required as a control.

Description:

For the treatment of P.vivax the standard treatment is chloroquine. There is a growing body of evidence suggesting that pregnant women may require different doses of drugs, including antimalarials, due to the physiological changes of pregnancy. It is important that any drug used in pregnant women is given at the correct dose. The only way to evaluate this is by pharmacokinetic studies. We propose to evaluate the pharmacokinetics of chloroquine when use to treat P.vivax in the 2nd or 3rd trimester of pregnancy. The same evaluation in the same woman post-partum is required as a control.

The two most recent pharmacokinetic publications conclude differently on chloroquine dosing in pregnant women: one suggests no dose adjustment and the other that a higher dose is probably needed. It is crucial that pregnant women are dosed correctly to maximise cure and minimize the chance for recurrence and the harmful effects of malaria. The proposed study on the pharmacokinetics of chloroquine treatment in pregnant women will solve this dilemma.

Pregnant women on the Thai-Burmese border are encouraged to attend antenatal care often for early detection and treatment of malaria. Low birth weight due to P.vivax affects primigravida and multigravida, not just primarily primigravida as with P.falciparum(highlighted in the attached reference). Hence it is important to consider these women for radical cure. This is not possible during pregnancy as primaquine is contraindicated so the next best time is in the post-partum period. During the post-partum period the woman remains in close contact with midwives for infant care and for their personal health. The midwives also have a record of malaria attacks during pregnancy.

We know more about chloroquine than any other antimalarial used in pregnancy. It has been widely used for prevention and treatment of malaria in pregnancy and in women with autoimmune disease such systemic lupus and rheumatoid arthritis high doses of hydroxychloroquine have been given daily including during the first trimester of pregnancy. Although data from prospective clinical trials of malaria are limited, this drug is considered safe in all trimester of pregnancy and in lactation.

For treatment of uncomplicated P.vivax WHO recommends chloroquine and primaquine where P.vivax remains chloroquine sensitive. A 14 day course of primaquine is recommended for radical cure of P.vivax. WHO advises not to use primaquine during pregnancy or in severe G6PD. WHO permits the use of primaquine during lactation if the breast fed infant is not G6PD deficient.

The possibility that women with recurrent P.vivax in the same pregnancy may have chloroquine resistant P.vivax needs to be considered. While the combination of chloroquine and primaquine cannot be used in pregnancy and the safety and efficacy of ACTs are still undergoing evaluation we need to explore alternatives to chloroquine for such cases. ACTs are recommended for chloroquine resistant P.vivax by WHO and one ACT considered safe in pregnancy and lactation is a 7 day course of artesunate-clindamycin.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 49
• Est. completion date: May 2017
• Est. primary completion date: November 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Age 18-50 years

• Gestational age (ultrasound confirmed) > 13.0 weeks

• Viable fetus as assessed by ultrasound scanning

• Microscopically confirmed uncomplicated P.vivax malaria

• Willingness and ability to comply with the study protocol for the duration of the trial

• Written informed consent provided

• No signs of labour

Exclusion Criteria:

• Known hypersensitivity to chloroquine

• Clinical or laboratory features of severe malaria based on WHO criteria-Appendix 1

• Gastrointestinal dysfunction that could alter absorption or motility

• History or known liver diseases or other chronic diseases (excluding thalassaemia & G6PD deficiency)

• Presence of intercurrent illness or any condition which in the judgement of the investigator would place the patient at undue risk or interfere with the results of the study

• Splenectomy

• Hematocrit (HCT) < 20% (based on field reading i.e. capillary sample)

• Taking contraindicated medications

• History of narcotic or alcohol abuse

Related Conditions & MeSH terms

• Malaria
• Malaria, Vivax
• Vivax Malaria

Intervention

Drug:
• Chloroquine
Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg). Dosing will be at 0, 24, 48 hrs with 10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2.

Locations

Country	Name	City	State
Thailand	Shoklo Malaria Research Unit	Tak	Mae Sot

Sponsors (1)

Lead Sponsor	Collaborator
University of Oxford

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Population Pharmacokinetics of Chloroquine	Population pharmacokinetic parameters up to day 63 in pregnant women with uncomplicated P.vivax malaria, and in the same women post-partum with P.vivax or without P.vivax.	63 days
Secondary	Relationship between pharmacokinetics and symptoms	Chloroquine pharmacokinetics versus symptomatology	63 days
Secondary	Efficacy of Chloroquine	Chloroquine efficacy against P.vivax	63 days
Secondary	Reticulocyte counts	Effect of chloroquine treatment on reticulocyte counts	63 days
Secondary	Pregnancy outcomes	Pregnancy outcomes (abortions, low birth weight, premature birth, congenital abnormality, stillbirths, neonatal and infant mortality)	63 days